Why Cancer Treatment Should Start with Genomics, Not Chemotherapy
When it comes to cancer treatment, chemotherapy, immunotherapy, or targeted therapy, genomics and biomarkers are often used—but not always in the right order. For many patients cancer care still follows outdated patterns in oncology, where tumor type dictates treatment instead of their unique cancer biology. This approach delays access to the most effective cancer treatment and reduces the chances of optimal outcomes.
Why Cancer Treatment Often Starts Backwards
In modern oncology, many patients begin with chemotherapy or generalized radiation before exploring targeted therapy or immunotherapy. This is largely due to how drugs are tested and approved. It is a historical momentum, not a solid treatment decision.
New cancer treatments are typically studied in patients who have already failed standard care. As a result, even highly effective therapies may only be used later in treatment—when the tumor is more advanced or resistant.
From a cancer biology standpoint, this doesn’t make sense. The most precise and effective treatments should be used first, not last.
The Role of Genomics and Biomarker Testing in Cancer Treatment
Genomic testing and biomarker testing are among the most important tools in cancer care, yet they are often delayed or underutilized.
Genomics identifies mutations and signaling pathways driving tumor growth. Biomarkers—such as HER2 or PD-L1 proteins on tumor cells—help determine whether targeted therapy like antibody-drug-conjugates or immunotherapy will work.
When these tests are done early, they can:
- Identify the most effective cancer treatment options
- Avoid chemotherapy that has no chance of working
- Reduce unnecessary side effects
When they are done late, much of their value is lost.
Why Targeted Therapy and Immunotherapy Should Come First
Targeted therapy and immunotherapy are designed to act on specific features of a tumor. That precision often means:
- Higher effectiveness
- Lower toxicity
- Better long-term outcomes
Many patients can achieve significant responses—or even durable remission—when these therapies are used appropriately.
Chemotherapy, by contrast, is a broad approach. It affects all rapidly dividing cells, not just cancer cells, which is why chemotherapy side effects can be significant. It is what you use when you have no idea of the cancer's weaknesses or everything else has failed.
Chemotherapy Still Matters—But Timing Is Critical
Chemotherapy remains an important part of cancer treatment, especially for aggressive or advanced disease.
However, it was originally developed as a last-resort option. It works broadly, but it also causes damage to healthy tissue, including the bone marrow and the immune system.
Using chemotherapy first, before understanding the tumor’s genomics and biomarkers, can:
- Limit future treatment options
- Increase toxicity unnecessarily
- Increase the aggressiveness of any remaining cancer
- Miss opportunities for more effective therapies
A Better Approach to Cancer Care
A more effective cancer treatment strategy starts with understanding the tumor:
- Perform genomic testing and biomarker analysis immediately
- Identify the highest-value targeted therapy or immunotherapy
- Use precise treatments first
- Reserve chemotherapy for later if needed
Cancer treatment is not one-size-fits-all. The details matter—especially early decisions.
Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.